Use access key #2 to skip to page content.
$32.15 1.52 (4.96%)
5/16/2008 4:00 PM

Amylin Pharmaceuticals, Inc. (AMLN)

CAPS Rating:
**

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

View All Commentary (AMLN)

Recs

0

Avatar cuin103 (92.22) Submitted: 4/16/08 9:56 PM : Outperform Start Price: $30.80 AMLN Score: -0.38

Just a play in the biotech/big pharm acquisition game. Has some interesting drugs in pipeline that a big pharm e.g.Phizer should tuck into their thin pipeline. With a number of high revenue and margin drugs going off patent next 2-4 years something is going to have to give. Good use of all that cash!

Report this Post Replies: 0 | Reply

Featured Broker Partners